Top Markets
#1 Zora Zora +33.25%
#2 Axelar Axelar +22.71%
#3 Seeker Seeker +22.17%
#4 AI XOVIA AI XOVIA +20.93%
#5 Full Moon Full Moon +18.72%
#6 0G 0G +16.10%
#7 Notcoin Notcoin +12.78%
#8 rsERG rsERG +10.58%
#9 VVS Finance VVS Finance +10.41%
#10 Cryptopia Cryptopia +10.26%
Coin of the day
Zora Zora
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Eikon Therapeutics, Inc. Common Stock Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock

EIKN
Classement en actions #12325
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established... Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Prix de l'action
$11.03
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$597.15M
Changement (1 jour)
-4.25%
Changement (1 an)
-
Pays
US
Échange Eikon Therapeutics, Inc. Common Stock (EIKN)

Catégorie

Healthcare
Revenus pour Eikon Therapeutics, Inc. Common Stock (EIKN)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Eikon Therapeutics, Inc. Common Stock, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Eikon Therapeutics, Inc. Common Stock de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH